The effects of sulphasalazine on the production of second messenger compounds in human granulocytes have been characterised by various stimuli. The increases in cytosolic calcium, inositol trisphosphate, diacylglycerol, and phosphatidic acid (all important mediators of intracellular signal transduction) triggered by stimulation were inhibited by sulphasalazine. The metabolites 5-aminosalicylic acid and sulphapyridine were less potent inhibitors than the mother compound.
Sulphasalazine, a drug used for the treatment of inflammatory bowel disease,' has during the last decade also been shown to treat effectively other diseases of a presumably autoimmune nature, such as rheumatoid arthritis, ankylosing spondylitis,2 and psoriasis. 3 The aetiology of tissue injury in rheumatoid arthritis is unclear. A variety of cells, including granulocytes, have been suggested to contribute to the initiation and propagation of the immune response in the rheumatoid synovium. Kitsis and Weissmann4 have reviewed the role of the neutrophil granulocyte as a key player in the articular and extra-articular manifestations of rheumatoid arthritis. They compared rheumatoid joint inflammation to the Arthus reaction, a neutrophil dependent interaction in which repeated exposure to an antigen results in the formation of immune complexes and activation of complement, causing an influx of granulocytes and tissue destruction.
Sulphasalazine has been found to inhibit granulocyte activation, assessed as superoxide production by cells activated with serum treated zymosan,5 chemotactic peptide N-formyl-Lmethionyl-L-leucyl-L-phenylalanine (fMLP) 6 7 and immune complexes.8 Sulphasalazine has also been found to inhibit, for example, granulocyte chemotaxis,9 lymphocyte proliferation,'0 and interleukin 2 production" in addition to monocyte production of interleukin 1.12 We have previously found by using the granulocyte as a model system that sulphasalazine inhibits cellular activation before activation of protein kinase C by interference with the synthesis of phosphoinositide derived second messenger compounds.6 As several cell types utilise phosphoinositide dependent signal transduction, sulphasalazine may modify a principal common mechanism for the regulation of cell activity, which may explain the beneficial effects of the drug in a variety of diseases.
Many of the stimuli used in the earlier studies trigger an increase in cytosolic calcium as part of the activation sequence. The increase in calcium has, in a variety of cell systems, been found to depend on remodelling of phosphoinositides'3 (see fig 1) . Ligation of a cell receptor leads to the phospholipase C dependent hydrolysis of phosphatidylinositol-4,5-bisphosphate generating two triggers of cell responses, namely diacylglycerol, an activator of protein kinase C,14 and inositol-1,4,5-trisphosphate, which triggers the release of cell associated calcium. 13 The link between the receptor and phospholipase C is in many cells a guanosine 5'-trisphosphate (GTP) binding protein. '5 Several drugs have been shown to modulate granulocyte responses such as superoxide production,16 and a few studies have indirectly associated the drug action with an interaction with the synthesis of phosphoinositide derived second messenger molecules '7 18 and the GTP binding protein. '9 The purpose of this study was to evaluate whether the inhibitory effects of sulphasalazine on cellular activation were related to the production of second messenger compounds. We found that sulphasalazine inhibited the production of inositol-1,4,5-trisphosphate and consequently the increase in cytosolic calcium, which indicated an interaction with either the plasma membrane receptor, the associated GTP binding protein, or the phospholipase C. Time (s) Figure 2 Changes in cytosolic calcium in granulocytes stimulated with 10 nM N-formyl-L-methionyl-L-leucyl-Lphenylalanine (fMLP). Effect of 120 seconds preincubation with 10 MM suphasalazine. The arrow indicates the addition offMLP. 
nmol/l (six subjects) and 126 (69) nmol/l (nine subjects) respectively for 1 and 10 nM fMLP. Table 2 shows that sulphasalazine inhibited the increase in cytosolic calcium. At a concentration of only 5 ,umol/I almost 50% of the response to 1 nM fMLP was inhibited in the absence of extracellular calcium. Sulphapyridine was considerably less potent. 5-Aminosalicylic acid was not studied due to its substantial intrinsic fluorescence at the excitation wavelengths applied. GTP (fig 3A) . Initial experiments showed that the maximum concentration of phosphatidic acid was obtained after 30-60 seconds, which agrees with earlier data.27 Table   5 shows that sulphasalazine (100 pmol/l) was a potent inhibitor of phosphatidic acid formation after 30 and 120 seconds, also 10 [tM sulphasalazine inhibited the reaction significantly.
Sulphapyridine (100 ttmol/l) inhibited the reaction slightly whereas 5-aminosalicylic acid was inactive.
Phosphatidic acid is metabolised to diacylglycerol27 and the diacylglycerol synthesis consequently lagged behind the phosphatidic acid synthesis (fig 3B) in time, which agrees with earlier results.3' The synthesis of diacylglycerol was inhibited by sulphasalazine (table   5 ).
An accelerating increase in the concentration of phosphatidic acid after stimulation with 20 mM fluoride was seen for at least 10 minutes. Table 5 shows that 100 tiM sulphasalazine inhibited the synthesis of phosphatidic acid by 56% after five minutes of stimulation.
Phosphatidic acid was produced in cells activated with PMA, essentially as described previously.3' No inhibitory effect of 100 FiM sulphasalazine was found after five minutes (table 5) .
Discussion
This study has shown that sulphasalazine inhibits the activation of human granulocytes through inhibition of the production of second messenger compounds derived from the GTP binding protein mediated activation of phospholipases C and D.
In the first set of experiments it was shown that sulphasalazine inhibited the phospholipase C dependent synthesis of inositol-1,4,5-trisphosphate from phosphatidylinositol-4,5-bisphosphate as well as the increase in cytosolic calcium in granulocytes. The latter inhibition may be secondary to the inhibition of inositol-1,4,5-trisphosphate synthesis, as cytosolic calcium is released by the action of inositol-1,4,5-trisphosphate. When a low concentration of fMLP (1 nmol/l) was used to stimulate the release of intracellular calcium, the inhibitory potency of sulphasalazine was increased (table 2) that sulphasalazine inhibited granulocyte superoxide production better at lower fMLP concentrations. Kanerud et al32 found, by using a single excitation wavelength, that 10 FtM sulphasalazine inhibited the increase in cytosolic calcium in granulocytes stimulated with 100 nM fMLP.
These inhibitory effects of sulphasalazine showed that the drug affected the intracellular signalling system either at the level of plasma membrane receptor, the GTP binding protein coupled to the receptor, or the enzymatic activity of phospholipase C. 5 The first possibility ( 34 which emphasises that the phosphatidic acid is more than a precursor, or a metabolite, of diacylglycerol.
The synthesis of phosphatidic acid by granulocytes labelled with glycerol was inhibited by sulphasalazine, thus confirming, our earlier results using cells labelled with phosphate-32.6 As in these earlier measurements, the recorded phosphatidic acid was mainly derived from diacylglycerol phosphorylated with phosphate-32 by the action of diacylglycerol kinase, the effect of sulphasalazine might have been due to inhibition of either the diacylglycerol kinase or to the synthesis of diacylglycerol.
The inhibition of the phosphatidic acid synthesis by sulphasalazine was similar in magnitude in cells with unspecifically (glycerol) labelled phospholipids and in cells specifically labelled in phosphatidylcholine. This similarity agrees with some studies which have shown that almost all the diacylglycerol formed during cell activation emanates from dephosphorylation of phosphatidic acid produced by phospholipase D mediated hydrolysis of phosphatidylcholine. 27 The effects of sulphasalazine on phospholipase D mediated degradation of phosphatidylcholine were studied by specific labelling of this phospholipid. Sulphasalazine inhibited the synthesis of phoshatidic acid and the subsequent formation of diacylglycerol in cells activated with fMLP. Fluoride induced activation was also inhibited, again demonstrating that the effect of sulphasalazine was not interaction with a plasma membrane receptor. Sulphasalazine did not inhibit PMA induced phospholipase D activity, which clearly shows that the drug did not inhibit phospholipase D, but interfered with an earlier step in the fMLP and fluoride induced activation of this enzyme.
The mechanisms of hormone induced phosphatidylcholine hydrolysis are not known to the same extent as for phosphoinositide hydrolysis. Stimulation of granulocytes with fMLP or fluoride induces phospholipase D mediated phosphatidylcholine hydrolysis in addition to phospholipase C mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate. As cell stimulation with calcium ionophores and protein kinase C activating phorbol esters activates phospholipase D without phospholipase C involvement,3' it is possible that phospholipase D activation requires previous phospholipase C mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate, leading to protein kinase C activation by diacylglycerol and increased cytosolic Ca2" by inositol-l ,4,5-trisphosphate.35
If so, the inhibition of sulphasalazine or the synthesis of phosphatidylcholine derived phosphatidic acid seen in this study is the consequence of a previous inhibition of phospholipase C. Alternatively, phospholipase D may not require previous phospholipase C activity but may be linked to a GTP binding protein, perhaps different from that linked to phospholipase C,35 36 with the possibility that sulphasalazine may also interact with this GTP binding protein.
It can be concluded from the results of this study that sulphasalazine inhibited cellular activation by interaction with the synthesis of phosphoinositide derived second messenger compounds at the level of phospholipase C or its regulatory GTP binding protein. Sulphasalazine also inhibited the synthesis of the putative second messenger phosphatidic acid, which may be due to either the same mechanism, or by interaction with a phospholipase D regulating GTP binding protein. The metabolites of sulphasalazine, 5-aminosalicylic acid and sulphapyridine, were less potent inhbitors than the mother compound.
